PULMPulmatrix, Inc.

Nasdaq pulmatrix.com


$ 1.85 $ -0.06 (-3.31 %)    

Thursday, 09-May-2024 15:59:23 EDT
QQQ $ 442.84 $ -0.57 (-0.13 %)
DIA $ 394.52 $ -0.66 (-0.17 %)
SPY $ 520.61 $ -0.23 (-0.04 %)
TLT $ 90.36 $ 0.25 (0.28 %)
GLD $ 216.28 $ -2.43 (-1.11 %)
$ 1.78
$ 1.85
$ 1.88 x 100
$ 0.00 x 0
$ 1.85 - $ 1.85
$ 1.55 - $ 2.98
44,325
na
6.5M
$ 0.75
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-30-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-29-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-11-2021 03-31-2021 10-Q
14 03-23-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-07-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 03-26-2020 12-31-2019 10-K
19 11-01-2019 09-30-2019 10-Q
20 08-05-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 02-19-2019 12-31-2018 10-K
23 11-14-2018 09-30-2018 10-Q
24 08-03-2018 06-30-2018 10-Q
25 05-11-2018 03-31-2018 10-Q
26 03-13-2018 12-31-2017 10-K
27 11-09-2017 09-30-2017 10-Q
28 08-04-2017 06-30-2017 10-Q
29 05-05-2017 03-31-2017 10-Q
30 03-10-2017 12-31-2016 10-K
31 11-04-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 03-10-2016 12-31-2015 10-K
35 11-12-2015 09-30-2015 10-Q
36 08-14-2015 06-30-2015 10-Q
37 06-10-2015 03-31-2015 10-K
38 02-13-2015 12-31-2014 10-Q
39 11-13-2014 09-30-2014 10-Q
40 08-14-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 pulmatrix-q4-eps-057-beats-104-estimate-sales-220m-beat-177m-estimate

Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(1.04) by ...

 pulmatrix-stops-pur1900-phase-2b-study-patient-enrollment-and-closing-study-in-agreement-with-partner-cipla-to-preserve-cash-and-facilitate-strategic-alternatives

Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to ...

 pulmatrix-q3-eps-103-beats-105-estimate-sales-175m-miss-186m-estimate

Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.05) by ...

 stocks-that-hit-52-week-lows-on-wednesday

  On Wednesday, 311 stocks hit new 52-week lows.

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 386 stocks made new 52-week lows.

 pulmatrix-announces-fda-acceptance-of-ind-application-for-pur3100-to-treat-acute-migraine

Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation...

 stocks-that-hit-52-week-lows-on-friday

  Friday's session saw 225 companies set new 52-week lows.

 stocks-that-hit-52-week-lows-on-wednesday

  On Wednesday, 59 companies achieved new lows for the year.

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 99 stocks hit new 52-week lows.

 pulmatrix-announces-publication-on-physiologically-based-pharmacokinetic-modelling-of-potential-drug-drug-interactions-with-pur1900-orally-inhaled-itraconazole

Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is administered with medicati...

 hc-wainwright--co-reiterates-buy-on-pulmatrix-maintains-10-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Pulmatrix (NASDAQ:PULM) with a Buy and maintains $10 price target.

 pulmatrix-q2-eps-104-up-from-136-yoy-sales-184m-up-from-133m-yoy

Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.04) per share. This is a 23.53 percent increase over losses of $(1.36)...

 pulmatrix-announces-submission-of-ind-application-to-fda-to-initiate-a-phase-2-trial-of-investigational-drug-pur3100-to-treat-acute-migraine

Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage biopharmaceutical company develo...

 stocks-that-hit-52-week-lows-on-monday

  On Monday, 120 stocks hit new 52-week lows.

 hc-wainwright--co-reiterates-buy-on-pulmatrix-maintains-10-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Pulmatrix (NASDAQ:PULM) with a Buy and maintains $10 price target.

 pulmatrix-q1-eps-122-up-from-151-yoy-sales-150m-up-from-116m-yoy

Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.22) per share. This is a 19.21 percent increase over losses of $(1.51)...

 stocks-that-hit-52-week-lows-on-thursday

  On Thursday, 185 companies achieved new lows for the year.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION